 | |
| Clinical data | |
|---|---|
| Other names | 3,4-Ethylenedioxy-N-methylamphetamine; EDMA; MDMC |
| Routes of administration | Oral[1] |
| Drug class | Psychoactive drug |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Duration of action | 3–5 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C12H17NO2 |
| Molar mass | 207.273 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
3,4-Ethylenedioxy-N-methylamphetamine (EDMA) is apsychoactive drug of thephenethylamine,amphetamine, andEDxx families.[1][2] It is ananalogue ofMDMA where themethylenedioxyring has been replaced by anethylenedioxy ring.[1][2] EDMA was first synthesized byAlexander Shulgin.[1] In his bookPiHKAL, the dose is listed as 150 to 250 mg and the duration as 3 to 5 hours.[1] According to Shulgin, EDMA produces only mild effects that includedparesthesia,nystagmus, adozing state,hypnogogicimagery, andcolored letters in the peripheral visual field.[1]
It has been found that EDMA acts as a non-neurotoxicserotonin releasing agent with moderately diminishedpotency relative to MDMA, and with negligible effects ondopamine release.[2] However, subsequent research found that EMDA is aserotonin–norepinephrine–dopamine releasing agent (SNDRA) withEC50Tooltip half-maximal effective concentration values of 117 nM for serotonin release, 325 nM for norepinephrine release, and 597 nM for dopamine release in rat brainsynaptosomes.[3] Compared to MDMA, EDMA was about half as potent as a serotonin releaser, 4.5-fold less potent as a norepinephrine releaser, and 8-fold less potent as a dopamine releaser.[3] The activities of the individualenantiomers of EDMA have also been assessed.[3]
